	ed States Paten	IT AND TRADEMARK OFFICE	UNITED STATES DEPAR United States Patent and Address: COMMISSIONEER P.O. Box 1450 Alexandria, Virginia 22 www.uspto.gov	FOR PATENTS		
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
12/407,556	03/19/2009	Roy G. Gordon	42697.135-US7	7572		
23483 WILMERHAL	7590 01/12/201 E/BOSTON	2	EXAM	INER		
60 STATE STE BOSTON, MA	REET		CHEN, BRET P			
D05101, MA	02109		ART UNIT	PAPER NUMBER		
			1715			
			NOTIFICATION DATE	DELIVERY MODE		
			01/12/2012	ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

teresa.carvalho@wilmerhale.com whipusptopairs@wilmerhale.com

	Application No.	Applicant(s)
	12/407,556	GORDON ET AL.
Office Action Summary	Examiner	Art Unit
	BRET CHEN	1715
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the	correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailir earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATIO 136(a). In no event, however, may a reply be the will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).
Status		
1) Responsive to communication(s) filed on		
	— s action is non-final.	
3) An election was made by the applicant in resp	oonse to a restriction requirement	set forth during the interview on
; the restriction requirement and electio	n have been incorporated into this	s action.
4) Since this application is in condition for allowa	ance except for formal matters, pr	osecution as to the merits is
closed in accordance with the practice under	<i>Ex parte Quayle</i> , 1935 C.D. 11, 4	53 O.G. 213.
Disposition of Claims		
5) Claim(s) <u>1-20</u> is/are pending in the application 5a) Of the above claim(s) is/are withdra		
6) Claim(s) is/are allowed.		
7) Claim(s) is/are rejected.		
8) Claim(s) is/are objected to.		
9) Claim(s) <u>1-20</u> are subject to restriction and/or	election requirement.	
Application Papers		
10) The specification is objected to by the Examin	er.	
11) The drawing(s) filed on is/are: a) acc		Examiner.
Applicant may not request that any objection to the		
Replacement drawing sheet(s) including the correct	tion is required if the drawing(s) is ob	pjected to. See 37 CFR 1.121(d).
12) The oath or declaration is objected to by the E	xaminer. Note the attached Office	e Action or form PTO-152.
Priority under 35 U.S.C. § 119		
 13) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 	n priority under 35 U.S.C. § 119(a	u)-(d) or (f).
1. Certified copies of the priority documen	ts have been received.	
2. Certified copies of the priority documen	ts have been received in Applicat	ion No
3. Copies of the certified copies of the price	prity documents have been receiv	ed in this National Stage
application from the International Burea	au (PCT Rule 17.2(a)).	
* See the attached detailed Office action for a list	t of the certified copies not receive	ed.
Attachment(s)	4) Interview Summary	(PTO 412)
 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 	Paper No(s)/Mail D	Date
3) Information Disclosure Statement(s) (PTO/SB/08)	5) 🔲 Notice of Informal I	
U.S. Patent and Trademark Office	6) 🛄 Other:	
	Action Summary P	art of Paper No./Mail Date 20120106

DETAILED ACTION

Claims 1-20 are pending in this application, which is a CON of Serial Number 11/199032 now US Patent 7,507,848; which is a CON of Serial Number 10/381628 now US Patent 6,969,539; which is a 371 of PCT/US01/30507.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-10, drawn to a method, classified in class 427, subclass 255.31.

II. Claims 11-20, drawn to a product, classified in class 428, subclass 701.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make another and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case, the product as claimed can be made by another and materially different and materially different process such as sputtering.

Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above and there would be a serious search and/or examination burden if restriction were not required because at least the following reason(s) apply:

The search and prosecution of method and product claims present a serious burden.

Applicant is advised that the reply to this requirement to be complete <u>must</u> include (i) an election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

A telephone call was made to Mary Rose Scozzafava on January 3, 2012, to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRET CHEN whose telephone number is (571)272-1417. The examiner can normally be reached on 7:30am - 4:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Timothy Meeks can be reached on (571) 272-1423. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Bret Chen/ Primary Examiner, Art Unit 1715 1/6/12

						Appl	ication/(Cont	rol N	lo.		Applic Reexa	cant(s	s)/Pat tion	tent Unde) F
Index of Claims			12407556			GORDON ET AL.										
						Exan	niner					Art Ur	nit			
						BRE	T CHEN					1715				
✓	R	lejected		-	C	Cance	elled		N	Non-l	Ele	ected		Α	Ар	peal
=	4	Allowed		÷ Restricted I			Interf	fer	ence		0	Obje	ected			
Claims renumbered in the same order as presented by applicant). 🗆	R.1.47										
	CLA	AIM								DATE						
F	inal	Original	01/06/2	2012												
		1	÷													+
		2	÷													
		3	÷													
		4	÷													
		5	÷													
		6	÷													
		7	÷													
		8	÷													
		9	÷													
		10	÷													
		11	÷								\perp					
		12	÷								\downarrow					<u> </u>
		13	÷								\perp					<u> </u>
		14	÷								1					<u> </u>
		15	÷													
		16	÷								4					
		17	÷													<u> </u>
		18	÷													<u> </u>
		19	÷								1					<u> </u>
		20	÷													

Part of Paper No. : 20120106

	ed States Paten	T AND TRADEMARK OFFICE	UNITED STATES DEPAR United States Patent and Address: COMMISSIONER F P.O. Box 1450 Alexandria, Virginia 22: www.usplo.gov	FOR PATENTS
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/407,556	03/19/2009	Roy G. Gordon	42697.135-US7	7572
23483 WILMERHAL	7590 03/22/2012 E/BOSTON	2	EXAM	INER
60 STATE STE BOSTON, MA	REET		CHEN,	BRET P
DOSTON, MA	02109		ART UNIT	PAPER NUMBER
			1715	
			NOTIFICATION DATE	DELIVERY MODE
			03/22/2012	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

teresa.carvalho@wilmerhale.com whipusptopairs@wilmerhale.com

	Application No.	Applicant(s)						
	12/407,556	GORDON ET AL.						
Office Action Summary	Examiner	Art Unit						
	BRET CHEN	1715						
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the c	correspondence address						
 A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). 	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).						
Status								
1) Responsive to communication(s) filed on 09 M	March 2012.							
	s action is non-final.							
3) An election was made by the applicant in resp		set forth during the interview on						
; the restriction requirement and electio	•	•						
4) Since this application is in condition for allowa								
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims								
5) Claim(s) <u>1-10</u> is/are pending in the application	1.							
5a) Of the above claim(s) is/are withdra								
6) Claim(s) is/are allowed.								
7) Claim(s) $1-10$ is/are rejected.								
8) Claim(s) is/are objected to.								
9) Claim(s) are subject to restriction and/o	or election requirement.							
Application Papers								
10) The specification is objected to by the Examination	er.							
11) The drawing(s) filed on <u>19 March 2009</u> is/are:		o by the Examiner.						
Applicant may not request that any objection to the								
Replacement drawing sheet(s) including the correct	tion is required if the drawing(s) is ob	jected to. See 37 CFR 1.121(d).						
12) The oath or declaration is objected to by the E	xaminer. Note the attached Office	Action or form PTO-152.						
Priority under 35 U.S.C. § 119								
13) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:)-(d) or (f).						
1. Certified copies of the priority documen								
2. Certified copies of the priority documen								
3. Copies of the certified copies of the price	-	ed in this National Stage						
application from the International Burea		2d						
* See the attached detailed Office action for a list		çα.						
Attachmont/c)								
Attachment(s) 1) X Notice of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail D	ate						
3) Information Disclosure Statement(s) (PTO/SB/08)	5) 🗌 Notice of Informal F	Patent Application						
Paper No(s)/Mail Date U.S. Patent and Trademark Office	6) 🗌 Other:							
	Action Summary Pa	art of Paper No./Mail Date 20120315						

DETAILED ACTION

Claims 1-10 are pending in this application, which is a CON of Serial Number 11/199032 now US Patent 7,507,848; which is a CON of Serial Number 10/381628 now US Patent 6,969,539; which is a 371 of PCT/US01/30507.

The preliminary amendment dated 3/9/12 canceling claims 11-20 has been entered. In view of said amendment, the restriction requirement has been withdrawn.

Specification

The disclosure is objected to because of the following informalities listed below.

Appropriate correction is required.

In the first paragraph of the specification, the lineage of the parent applications should be updated to reflect maturation into a US Patent.

The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all

obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Aarik et

al. (Thin Solid Films article) in view of Vaartstra (6,159,855).

Aarik discloses an ALD method of growing hafnium dioxide from $HfCl_4$ and H_2O (abstract) in which the reactants are introduced into a hot wall ALD reactor in alternating pulses (p.111 col.1 and Figure 1). However, the reference fails to teach a metal alkylamide.

Vaartstra discloses organometallic compound mixtures for use in chemical vapor deposition (title) in which metalloamide compounds are used (col.2 line 48- col.3 line 6). In one embodiment, the metalloamide compounds can be a variety of compounds including tetrakis-(diethylamido)-hafnium and tetrakis-(diethylamido)-zirconium (col.6 lines 19-56). It would have been obvious to incorporate same in the process of Aarik with the expectation of obtaining similar results because Vaartstra teaches the conventionality of using metalloamide compounds as precursors in a vapor deposition process.

Regarding claim 2, Aarik teaches of using hafnium dioxide as an insulator in electronic devices (p.110 col.1).

Regarding claim 3, Aarik teaches the use of tetrakis-(diethylamido)-hafnium (col.6 lines 19-56).

Regarding claims 4-5, Aarik teaches the use of tetrakis-(diethylamido)-hafnium, tetrakis-(diethylamido)-zirconium, and tetrakis-(dimethlamido)-zirconium (col.6 lines 19-56). Given

such a teaching, one skilled in the art would reasonably expect that tetrakis-(ethylmethylamido) - hafnium could be utilized to form a hafnium dioxide film with the expectation of success in the absence of a showing of unexpected results. The same issue applies to tetrakis-(dimethylamido)-hafnium.

Regarding claim 6, Aarik teaches the use of tetrakis-(diethylamido)-hafnium (col.6 lines 19-56)

Regarding claim 7, Aarik teaches the use of tetrakis-(diethylamido)-zirconium and tetrakis-(dimethlamido)-zirconium (col.6 lines 19-56).

Regarding claim 8, Aarik teaches the use of tetrakis-(diethylamide)-hafnium, tetrakis-(diethylamido)-zirconium, and tetrakis-(dimethylamido)-zirconium (col.6 lines 19-56). Given such a teaching, one skilled in the art would reasonably expect that tetrakis-(ethylmethylamido) zirconium could be utilized to form a zirconium oxide film with the expectation of success in the absence of a showing of unexpected results.

Regarding claim 9, Aarik teaches the use of tetrakis-(dimethylamido)-zirconium (col.6 lines 19-56).

Regarding claim 10, Aarik teaches the use of tetrakis-(diethylamido)-zirconium (col.6 lines 19-56).

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-10 are rejected on the ground of nonstatutory obviousness-type double

patenting as being unpatentable over claims 24-31 of U.S. Patent No. 6,969,539 in view of

Vaartstra (6,159,855).

Gordon et al. (6,969,539) teaches a process for forming a metal oxide, comprising:

exposing a heated surface alternately to the vapor of one or more metal amides having an amido

group selected from the group consisting of dialkylamido, disilylamido and (alkyl)(silyl) amido

moieties, and then to the vapors of water or an alcohol (claim 24), which is similar to the instant

claim 1. However, the reference fails to specifically teach a metal alkylamide.

Vaartstra discloses organometallic compound mixtures for use in chemical vapor

deposition (title) in which metalloamide compounds are used (col.2 line 48- col.3 line 6). In one

embodiment, the metalloamide compounds can be a variety of compounds including tetrakis-

(diethylamido)-hafnium and tetrakis-(diethylamido)-zirconium (col.6 lines 19-56). It would

have been obvious to incorporate same in the process of Gordon with the expectation of

obtaining similar results because Vaartstra teaches the conventionality of using metalloamide

compounds as precursors in a vapor deposition process.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRET CHEN whose telephone number is (571)272-1417. The examiner can normally be reached on 7:30am - 4:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Timothy Meeks can be reached on (571) 272-1423. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Bret Chen/ Primary Examiner, Art Unit 1715 3/15/12

LISTING OF CLAIMS

1. (Currently Amended): A process for making an insulator in a microelectronic

device, the process comprising:

introducing a first reactant component into a deposition chamber;

introducing a second reactant component into the deposition chamber; and

alternately repeating introducing the first reactant component and the second reactant

component into the deposition chamber;

wherein deposition of the first reactant component and the second reactant

component are self-limiting;

wherein said first reactant component comprises a metal alkylamide;

wherein said second reactant component interacts with the deposited first reactant

component to form the insulator; and

wherein said insulator comprises oxygen and the metal from the metal alkylamide.

- (Original): The process as in claim 1, wherein the insulator insulates a gate or a capacitor.
- (Original): The process in claim 2, wherein the metal alkylamide is a hafnium dialkylamide.
- 4. (Original): The process as in claim 3, wherein the hafnium dialkylamide is tetrakis(ethylmethylamido)hafnium.

ACTIVEUS 100814010v1

- (Original): The process as in claim 3, wherein the hafnium dialkylamide is tetrakis(dimethylamido)hafnium.
- (Original): A process as in claim 3, wherein the hafnium dialkylamide is tetrakis(diethylamido)hafnium.
- (Original): A process as in claim 2, wherein the metal alkylamide is a zirconium dialkylamide.
- (Original): A process as in claim 7, wherein the zirconium dialkylamide is tetrakis(ethylmethylamido)zirconium.
- 9. (Original): A process as in claim 7, wherein the zirconium dialkylamide is tetrakis(dimethylamido)zirconium.
- (Original): A process as in claim 7, wherein the zirconium dialkylamide is tetrakis(diethylamido)zirconium.
- 11-20. (Cancelled).

Docket No.: 0042697.00135 US7 (HU 1824)

REMARKS

I. Objections to the Specification

The first paragraph of the specification has been amended to reflect maturation of the parent applications into U.S. Patents as requested by the Examiner. Withdrawal of the objection is requested.

II. Amendments to the Claims

Claim 1 is amended. Support for the amendments can be found throughout the specification. For example, support can be found at page 27, line 23 – page 28, line 12 of the originally filed specification. No new matter is added.

III. Rejections under 35 U.S.C. §103(a) and Double Patent Rejection

Claims 1-10 have been rejected under 35 U.S.C. §103(a) over Aarik et al. (Thin Solid Films article) in view of Vaartstra (U.S. Patent No. 6,159,855). Claims 1-10 have also been rejected under nonstatutory obviousness-type double patenting over claims 24-31 of Gordon (U.S. Patent No. 6,969,539) in view of Vaartstra. Applicants respectfully request reconsideration in light of the amendments to the claims and the comments that follow.

Claim 1, as amended, is directed to, *inter alia*, "introducing a first reactant component into a deposition chamber; introducing a second reactant component into the deposition chamber; and *alternately repeating* introducing the first reactant component and the second reactant component into the deposition chamber, *wherein deposition of the first reactant component and the second reactant component are self-limiting*." (Emphases added.) In other words, claim 1 is directed to an *alternating layer deposition (ALD)* process.

Claims 24-31 of Gordon is directed to a "process for forming a metal oxide comprising exposing a heated surface *alternately* to the vapor of one or more metal amides having an amido group selected from the group consisting of dialkylamido, disilylamido and (alkyl)(silyl) amido moieties, *and then* to the vapors of water or an alcohol." (Emphasis added.)

Aarik describes an "<u>*ALD*</u> method of growing hafnium dioxide from $HfCl_4$ and H_2O (abstract) in which the reactants are introduced into a hot wall <u>*ALD*</u> reactor in alternating pulses (p. 111 col. 1 and Figure 1)." (Office Action, page 3; emphases added.) However, as the Office Action recognizes, Aarik "fails to teach a metal alkylamide." (*Id*.)

To remedy the deficiencies of Aarik and Gordon, the Office Action asserts that because "Vaartstra discloses organometallic compound mixtures *for use in chemical vapor deposition* (title) in which metalloamide compounds are used" (Office Action, page 3), Vaartstra can be combined with Aarik. The Office Action further asserts that Vaartstra and Gordon are also combinable for the same reason. Applicants respectfully disagree.

Both CVD and ALD require a volatile source of precursor. However, both CVD and ALD entail using precursor compounds that have particular types of chemical reactivity particularly suited for each of the deposition techniques. For example, ALD specifically requires precursors that can provide self-limiting growth during deposition, which is not needed in CVD techniques. In fact, for CVD to occur, Applicants submit that one of ordinary skill would want a continuous growth during deposition, *not* a self-limited growth during deposition. In contrast, for ALD, a self-limited growth is desired. Accordingly, many compounds that have been utilized for CVD process are not necessarily capable of being utilized in an ALD process, as it cannot be predicted whether certain precursors will be able to achieve the self-limited growth that is needed for ALD.

As support, Applicants submit herewith a review article by Jones, A.C., et al., "MOCVD and ALD of High-K Dielectric Oxides Using Alkoxide Precursors," Chemical Vapor Deposition, volume 12, pages 83-98 (2006). The conclusion of this paper, on page 96, shows that a large class

of compounds developed to be particularly effective as CVD precursors, failed to achieve the selflimited growth that is needed for ALD precursors. Hence, even as late as 2006, one of ordinary skill in the art could not predict a priori whether certain precursors useful for CVD can or cannot be utilized in ALD. Nevertheless, Applicants have determined that the particular claimed metal alkylamides do indeed provide the self-limiting growth characteristics needed for a successful ALD process. There is no teaching or suggestion in Vaartstra that any of the precursors described therein can provide a self-limited growth during deposition.

Many other reviews of CVD can be cited, none of which even mentions self-limited reactivity, a property that is important to the performance of ALD. (*See, e.g.,* L. McElwee-White, "Design of precursors for the CVD of inorganic thin films," Dalton Transactions, pages 5327-5333 (2006); G. G. Condorelli et al., "Engineering of molecular architectures of β -diketonate precursors toward new advanced materials," Coordination Chemistry Reviews, volume 251, pages 1931-1950 (2007); K. L. Choy, "Chemical vapour deposition of coatings," Progress in Materials Science, volume 48, pages 57-170 (2003); "Chemical Vapor Deposition," Kirk-Othmer Encyclopedia of Chemical Technology (John Wiley & Sons), volume 5, pages 803-813.) Thus, the mere mention of a precursor as useful in CVD does not necessarily inform one of ordinary skill in the art whether it can be utilized in an ALD process as well.

Moreover, the Office Action fails to provide specific technical reasons why one of ordinary skill in the art, at the time the instant original application was filed, would have expected the precursors that were useful in CVD, as described in Vaartstra, would also equally be useful in an ALD process.

Accordingly, withdrawal of the rejections is respectfully requested.

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

 23483
 7590
 10/10/2012

 WILMERHALE/BOSTON
 60
 STATE STREET

 BOSTON, MA 02109
 10/2012

EXAMINER CHEN, BRET P ART UNIT PAPER NUMBER

DATE MAILED: 10/10/2012

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/407,556	03/19/2009	Roy G. Gordon	42697.135-US7	7572

TITLE OF INVENTION: VAPOR DEPOSITION OF METAL OXIDES, SILICATES AND PHOSPHATES, AND SILICON DIOXIDE

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$885	\$300	\$0	\$1185	01/10/2013

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED</u>. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. <u>THIS STATUTORY PERIOD CANNOT BE EXTENDED</u>. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:	If the SMALL ENTITY is shown as NO:
A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.	A. Pay TOTAL FEE(S) DUE shown above, or
B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or	B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: <u>Mail</u> Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450

Alexandria, Virginia 22313-1450

or <u>Fax</u> (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fees will be mailed to the current correspondence address."

maintenance fee notificatio CURRENT CORRESPONDEN 23483 7 WILMERHALE 60 STATE STREI BOSTON, MA 02	Fe pa I St ad tra FIRST NAMED INVENTO	Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, mean have its own certificate of mailing or transmission. Certificate of Mailing or Transmission Interest of States Postal Service with sufficient postage for first class mail in an envelor addressed to the Mail Stop ISSUE FEE address above, or being facsim transmitted to the USPTO (571) 273-2885, on the date indicated below. (Depositor's nam (Bepositor's nam (Depositor's nam <td col<="" th=""></td>						
12/407,556 TITLE OF INVENTION: V	03/19/2009 VAPOR DEPOSITION	OF METAL OXIDES	Roy G. Gordon SILICATES AND PHOS	PHATES AND SIL		97.135-US7 DXIDE	7572	
				·				
APPLN. TYPE nonprovisional	SMALL ENTITY YES	ISSUE FEE DUE	PUBLICATION FEE DUI	E PREV. PAID ISSUI	E FEE	S1185	DATE DUE 01/10/2013	
			, ,	_{هر}		\$1105	01/10/2015	
EXAMIN CHEN, BE		ART UNIT 1715	CLASS-SUBCLASS 427-255310					
1. Change of correspondence			2. For printing on the	natent front nage lis	st			
CFR 1.363). Change of correspon Address form PTO/SB/ "Fee Address" indic PTO/SB/47; Rev 03-02 Number is required. 3. ASSIGNEE NAME ANI PLEASE NOTE: Unles recordation as set forth i (A) NAME OF ASSIGN	ation (or "Fee Address" or more recent) attache D RESIDENCE DATA s an assignee is identi in 37 CFR 3.11. Comp	' Indication form ed. Use of a Customer A TO BE PRINTED ON ' fied below, no assignee		tively, gle firm (having as a : agent) and the nam torneys or agents. If e printed. ype) patent. If an assign n assignment.	n member a les of up to no name is ee is ident	a 2 s 3 tified below, the do	ocument has been filed for	
Please check the appropriat	e assignee category or	categories (will not be p	rinted on the patent) : [Individual 🛛 Co	orporation	or other private gro	up entity 📮 Government	
 4a. The following fee(s) are Issue Fee Publication Fee (No Advance Order - # o 	small entity discount p	ermitted)	 b. Payment of Fee(s): (PI A check is enclosed Payment by credit c The Director is here overpayment, to Deposite the construction of the construction o	ard. Form PTO-2038	is attache	d.	·	
5. Change in Entity Status	`	,	b . Applicant is no lo	manu alaimina SMAL		W status See 27 CE	= 1.27(-)(2)	
NOTE: The Issue Fee and I interest as shown by the rec	Publication Fee (if requ	ired) will not be accepte	d from anyone other thar					
· · · · ·								
Authorized Signature								
Typed or printed name _				Registration N	lo			
This collection of informati an application. Confidentia submitting the completed a this form and/or suggestion Box 1450, Alexandria, Vir Alexandria, Virginia 22313 Under the Paperwork Redu	lity is governed by 35 upplication form to the is for reducing this bui ginia 22313-1450. DO -1450.	U.S.C. 122 and 37 CFR USPTO. Time will vary den, should be sent to th NOT SEND FEES OR (1.14. This collection is e depending upon the ind e Chief Information Offi COMPLETED FORMS	stimated to take 12 i ividual case. Any co cer, U.S. Patent and IO THIS ADDRESS	minutes to omments of Trademarl S. SEND T	complete, including n the amount of tin k Office, U.S. Depa 'O: Commissioner f	g gathering, preparing, and ne you require to complete rtment of Commerce, P.O. For Patents, P.O. Box 1450,	

OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	ted States Pate	NT AND TRADEMARK OFFICE	UNITED STATES DEPAR United States Patent and Address: COMMISSIONER F P.O. Box 1450 Alexandria, Virginia 223 www.uspto.gov	OR PATENTS
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/407,556	03/19/2009	Roy G. Gordon	42697.135-US7	7572
23483 75	90 10/10/2012		EXAN	IINER
WILMERHALE/ 60 STATE STREE			CHEN,	BRET P
BOSTON, MA 021			ART UNIT	PAPER NUMBER
			1715	
			DATE MAILED: 10/10/201	2

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 521 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 521 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability CORDON ET AL. Examiner Art Unit Image: Control of the provide state		Application No.	Applicant(s)					
Notice of Allowability Examiner Art Unit BET CHEN 1715 The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims boing allowable, PROSECUTION ON THE MERTS IS (CR BEMAINS) CLOSED in this application. If not included in the course. THIS within the previously male), a Nucle of Allowance (PTC-86) or other appropriate communication is aubject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. 1 This communication is response to a cash for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). 2 An election was made by the applicant in response to a restriction requirement and election have been incorporated into this action. 3 The allowed claim(s) is/are 1-10. 4 Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). 2 Certified copies of the priority documents have been received. 3 Copies of the certified copies of the priority documents have been received in his national stage application from the International Bursau (PCT Rule 17.2(a)). * Certified copies not received:								
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MENTS IS (OR REMINIS) CLOSED in this application. In clinicided herewith (or providus) mailed), a hotice of Allowance (FTOL-89) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT FIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. Is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. The application requirement set forth during the interview on	Notice of Allowability	,						
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MENTS IS (OR REMINIS) CLOSED in this application. In clinicided herewith (or providus) mailed), a hotice of Allowance (FTOL-89) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT FIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. Is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. The application requirement set forth during the interview on			1715					
All claims being allowable, PROSECUTION ON THE MENTS IS (OR REMAINS) CLOSED in this application. The included herewith or proviously mailed in a course. THS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MEEP 1308. 1. ② This communication is responsive to <u>9/6/12</u> 2. ③ An election was made by the applicant in response to a restriction requirement and election have been incorporated into this action. 3. ③ The allowed claim(s) is/are <u>1-10</u> 4. ③ Acknowledgment is made or a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). 3. ③ The allowed claim(s) is/are <u>1-10</u> 4. ③ Acknowledgment is made or a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). 3. ③ Chertified copies of the priority documents have been received in Application No		BREICHEN	1715					
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on; The restriction requirement and election have been incorporated into this action. 3. ③ The allowed claim(s) iterates 1_10. 4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). 5. ③ Charlied copies of the priority documents have been received. 7. ③ Cortified copies of the priority documents have been received in Application No 3. ③ Copies of the certified copies of the priority documents have been received in Application No 4. ③ Certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). 4. ③ Certified copies not received: 4. ③ Copies of the certified copies to the abundled. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATHER TAPPLICATION (PTO-152) which gives reason(s) why the cath or declaration is deficient. 5. ⑤ ASUBSTITUTE CATH ON DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATHENT APPLICATION (PTO-152) which gives reason(s) why the cath or declaration is deficient. 5. ⑥ CORRECTED DRAMINS (as replacement sheets) must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATHENT APPLICATION (PTO-152) which gives reason(s) why the cath or declaration is deficient. 6. ◎ CORRECTED DRAMINS (as replacement sheets) must be submitted. Note the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date	All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R	(OR REMAINS) CLOSED or other appropriate comm IGHTS. This application is	in this application. If not included nunication will be mailed in due course. THIS					
the restriction requirement and election have been incorporated into this action. 3.	1. \square This communication is responsive to <u>9/6/12</u> .							
A			h during the interview on;					
 a) □ AI □ b) □ Some* c) □ None of the: □ Certified copies of the priority documents have been received. □ Certified copies of the priority documents have been received in Application No □ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHE STROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. □ A SUBSTITUTE OATH OR DECLARATION must be submitted. (a) □ Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) □ hereto or 2) □ to Paper No./Mail Date (b) □ Including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) □ hereto or 2) □ to Paper No./Mail Date (b) □ Including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date (b) □ Including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date (b) □ Including changes required by the attached Examiner's Amendment / Comment or in the office action of Paper No./Mail Date balee(a south in the Adaet according to 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement here(s) and the labeled as such in the header according to 37 CFR 1.121(d). 7. □ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's Amendment / Comment 8. □ Interview Summary (PTO-413), Paper No./Mail Date <u>96/12,31/51/2</u> 8. □ Other	3. \blacksquare The allowed claim(s) is/are <u>1-10</u> .							
1. □ Cartified copies of the priority documents have been received in Application No		er 35 U.S.C. § 119(a)-(d) or	· (f).					
3. □ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received :		e been received.						
International Bureau (PCT Rule 17.2(a)). * Certified copies not received:	2. Certified copies of the priority documents have	e been received in Applicati	on No					
* Certified copies not received:	3. 🔲 Copies of the certified copies of the priority do	cuments have been receive	ed in this national stage application from the					
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDOMMENT of this application. THIS THREE-MONT PERIOD IS NOT EXTENDABLE. S A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the cath or declaration is deficient. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) are to or 2) be the paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date (b) and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1 Notice of References Cited (PTO-892) 2 Notice of Draftperson's Patent Drawing Review (PTO-948) 3 \sqrt{Interview Summary (PTO-413), Paper No./Mail Date /Bret Chen/ Primary Examiner', Art Unit 1715 US Patent and Trademark Office US Patent Application	International Bureau (PCT Rule 17.2(a)).							
noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. □ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 6. □ CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) □ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) □ hereto or 2) □ to Paper No./Mail Date (b) □ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date (b) □ including number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 7. □ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 5. □ Notice of Informal Patent Application 2. □ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5. □ Notice of Informal Patent Application 3. □ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 9/6/12, 3/15/12 7. □ Examiner's Statement of Reasons for Allowance 9. □ Other	* Certified copies not received:							
INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 6. □ CORRECTED DRAWINOS (as "replacement sheets") must be submitted. (a) □ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) □ hereto or 2) □ to Paper No./Mail Date (b) □ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date (aech sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 7. □ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 5. □ Notice of Informal Patent Application 9. □ Notice of Draftperson's Patent Drawing Review (PTO-948) 8. ☑ Examiner's Comment 9. □ Other	noted below. Failure to timely comply will result in ABANDONMENT of this application.							
(a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 5. Notice of Informal Patent Application 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 6. Interview Summary (PTO-413), Paper No./Mail Date 3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>9/6/12, 3/15/12</u> 7. Examiner's Comment Regarding Requirement for Deposit of Biological Material 9. Other								
1) hereto or 2) to Paper No./Mail Date (b)	6. CORRECTED DRAWINGS (as "replacement sheets") mus	t be submitted.						
(b) □ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 7. □ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 5. □ Notice of Informal Patent Application 2. □ Notice of Draftperson's Patent Drawing Review (PTO-948) 5. □ Notice of Informal Patent Application 3. ☑ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>9/6/12, 3/15/12</u> 7. □ Examiner's Comment Regarding Requirement for Deposit of Biological Material 8. ☑ Examiner's Chen/ 9. □ Other		-	w (PTO-948) attached					
Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 7								
each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 7. □ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1. ☑ Notice of References Cited (PTO-892) 5. □ Notice of Informal Patent Application 2. □ Notice of Draftperson's Patent Drawing Review (PTO-948) 6. □ Interview Summary (PTO-413), Paper No./Mail Date		s Amendment / Comment o	or in the Office action of					
attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1. \Bigstymbol{\Bigstyymbl{\Bigstyymbl{\Bigstymbol{\Bigstymbol{\Bigstymbol{\Big	each sheet. Replacement sheet(s) should be labeled as such in t	he header according to 37 C	FR 1.121(d).					
1. ⊠ Notice of References Cited (PTO-892) 5. □ Notice of Informal Patent Application 2. □ Notice of Draftperson's Patent Drawing Review (PTO-948) 6. □ Interview Summary (PTO-413), Paper No./Mail Date 3. ⊠ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>9/6/12, 3/15/12</u> 7. □ Examiner's Amendment/Comment 4. □ Examiner's Comment Regarding Requirement for Deposit of Biological Material 8. ⊠ Examiner's Statement of Reasons for Allowance 9. □ Other /Bret Chen/ Primary Examiner, Art Unit 1715 U.S. Patent and Trademark Office								
1. ⊠ Notice of References Cited (PTO-892) 5. □ Notice of Informal Patent Application 2. □ Notice of Draftperson's Patent Drawing Review (PTO-948) 6. □ Interview Summary (PTO-413), Paper No./Mail Date 3. ⊠ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>9/6/12, 3/15/12</u> 7. □ Examiner's Amendment/Comment 4. □ Examiner's Comment Regarding Requirement for Deposit of Biological Material 8. ⊠ Examiner's Statement of Reasons for Allowance 9. □ Other /Bret Chen/ Primary Examiner, Art Unit 1715 U.S. Patent and Trademark Office								
1. ⊠ Notice of References Cited (PTO-892) 5. □ Notice of Informal Patent Application 2. □ Notice of Draftperson's Patent Drawing Review (PTO-948) 6. □ Interview Summary (PTO-413), Paper No./Mail Date 3. ⊠ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>9/6/12, 3/15/12</u> 7. □ Examiner's Amendment/Comment 4. □ Examiner's Comment Regarding Requirement for Deposit of Biological Material 8. ⊠ Examiner's Statement of Reasons for Allowance 9. □ Other /Bret Chen/ Primary Examiner, Art Unit 1715 U.S. Patent and Trademark Office								
 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>9/6/12, 3/15/12</u> 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material /Bret Chen/ Primary Examiner, Art Unit 1715 U.S. Patent and Trademark Office 			aformal Detaut Annliastica					
3. ☑ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>9/6/12, 3/15/12</u> Paper No./Mail Date <u></u> 4. □ Examiner's Comment Regarding Requirement for Deposit of Biological Material 8. ☑ Examiner's Statement of Reasons for Allowance 9. □ Other /Bret Chen/ Primary Examiner, Art Unit 1715 U.S. Patent and Trademark Office								
Paper No./Mail Date <u>9/6/12, 3/15/12</u> 4. □ Examiner's Comment Regarding Requirement for Deposit of Biological Material 8. ⊠ Examiner's Statement of Reasons for Allowance 9. □ Other /Bret Chen/ Primary Examiner, Art Unit 1715 U.S. Patent and Trademark Office		Paper No	./Mail Date					
4. □ Examiner's Comment Regarding Requirement for Deposit of Biological Material 8. ☑ Examiner's Statement of Reasons for Allowance 9. □ Other /Bret Chen/ Primary Examiner, Art Unit 1715 U.S. Patent and Trademark Office		7. 🗌 Examiner's	s Amendment/Comment					
9. Other /Bret Chen/ Primary Examiner, Art Unit 1715	4. Examiner's Comment Regarding Requirement for Deposit	8. 🔀 Examiner's	s Statement of Reasons for Allowance					
/Bret Chen/ Primary Examiner, Art Unit 1715	of Biological Material	9. 🗖 Other						
U.S. Patent and Trademark Office			_					
U.S. Patent and Trademark Office		Ι						
U.S. Patent and Trademark Office								
	U.S. Patent and Trademark Office							

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

It is well known to form a metal oxide by ALD as noted by Aarik et al. (Thin Solid Films

article). With respect to the precursor, it is well known to utilize metal alkylamide to form an

oxide film by CVD as noted in Vaarstra (6,159,855). Furthermore, it is well known to utilize

metal alkylamide to form a titanium-silicon-nitride film by ALD (Applied Physics Letters

article). However, the prior art references fail to teach or suggest using alkylamide to form a

metal oxide film by ALD.

Any comments considered necessary by applicant must be submitted no later than the

payment of the issue fee and, to avoid processing delays, should preferably accompany the issue

fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for

Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRET CHEN whose telephone number is (571)272-1417. The examiner can normally be reached on 7:30am - 4:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Timothy Meeks can be reached on (571) 272-1423. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Bret Chen/ Primary Examiner, Art Unit 1715 9/26/12

Notice of References Cited	Application/Control No. 12/407,556	Applicant(s)/Patent Under Reexamination GORDON ET AL.		
Notice of hereichees offed	Examiner	Art Unit		
	BRET CHEN	1715	Page 1 of 1	

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification	
*	А	US-2006/0258078	11-2006	Lee et al.	438/216	
	В	US-				
	С	US-				
	D	US-				
	Е	US-				
	F	US-				
	G	US-				
	Н	US-				
	Ι	US-				
	J	US-				
	Κ	US-				
	L	US-				
	М	US-				

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	Ν					
	0					
	Ρ					
	Q					
	R					
	S					
	Т					

	NON-PATENT DOCUMENTS							
*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)						
	U	Min, Jae-Sik, et al., "Metal-organic atomic-layer deposition of titanium-silicon-nitride films". Applied Physics Letters, Volume 75, Number 11, 13 September 1999, pp.1521-1523.						
	v	Hausmann, Dennis M., et al., "Atomic Layer Deposition of Hafnium and Zirconium Oxides Using Metal Amide Precursors". Chem. Mater. Vol.14, No.10, 2002, 4350-4358.						
	w	Leskela, Markku, et al., "Review: Atomic layer deposition (ALD): from precursors to thin film structures." Thin Solid Films 409 (2002), pp.138-146.						
	x							

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

Part of Paper No. 20120926